Core Viewpoint - Innventure, Inc. is set to release its fourth quarter and full year 2025 financial results on March 30, 2026, with a conference call scheduled for the same day to discuss these results [1]. Group 1: Financial Results Announcement - The financial results will be released after market close on March 30, 2026 [1]. - A conference call will be held at 5:00 pm ET on the same day to discuss the results [1]. Group 2: Company Overview - Innventure, Inc. is an industrial growth conglomerate focused on building companies with billion-dollar valuations through the commercialization of breakthrough technology solutions [3]. - The company aims to bridge the "Valley of Death" between corporate innovation and commercialization by leveraging value-driven multinational partnerships, operational experience, and scaling expertise [3].

Core Insights - Worthington Enterprises Inc. reported strong financial performance for the third quarter of fiscal 2026, achieving year-over-year growth in adjusted EPS and EBITDA for the sixth consecutive quarter, driven by solid organic growth and the acquisition of LSI Group [3][6]. Financial Highlights - Net sales increased by 24% to $378.7 million compared to $304.5 million in the third quarter of fiscal 2025 [4][6]. - Operating income rose to $31.5 million, up from $20.9 million, reflecting higher net sales and improved fixed cost absorption [4][8]. - Net earnings increased by 15% to $45.1 million, while adjusted net earnings grew by 7% to $48.5 million [4][6]. - Adjusted EBITDA grew by 15% to $84.6 million from $73.8 million in the prior year quarter [4][6]. - Earnings per share (EPS) on a fully diluted basis improved to $0.92 from $0.79, and adjusted EPS increased to $0.98 from $0.91 [4][6]. Segment Performance - The Building Products segment generated net sales of $223.9 million, a 35.8% increase over the prior year, driven by higher volumes and acquisitions [13]. - The Consumer Products segment reported net sales of $154.8 million, a 10.8% increase, attributed to higher volumes and average selling prices [14]. Cash Flow and Capital Management - Net cash provided by operating activities was $61.9 million, an 8% increase from $57.1 million in the prior year [4][6]. - Free cash flow improved to $48.1 million from $44.4 million [4][6]. - The company repurchased 100,000 common shares for $5.4 million and declared a quarterly dividend of $0.19 per share [6][12]. Acquisition and Strategic Outlook - The acquisition of LSI Group for approximately $205 million is expected to enhance the Building Products segment [6][12]. - The company is positioned for continued growth, focusing on innovative solutions and disciplined capital deployment to enhance shareholder value [15].

Core Viewpoint - Hennessy Capital Investment Corp. VIII will allow holders of its units to separately trade Class A ordinary shares and rights starting March 30, 2026 [1] Company Overview - Hennessy Capital Investment Corp. VIII is a newly incorporated blank check company founded by Daniel J. Hennessy, aimed at executing mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations [3] - The company intends to focus its search for target businesses in the industrial innovation and energy transition sectors, although it reserves the right to pursue opportunities in any business or industry [3]

Core Viewpoint - Hub Group, Inc. has received a deficiency notice from Nasdaq due to the delayed filing of its Annual Report on Form 10-K for the year ended December 31, 2025, which is expected and does not immediately affect the trading of its common stock [1][3][4]. Group 1: Business Performance - In the first quarter of fiscal 2026, Hub Group reported steady intermodal volume performance despite winter storm disruptions, indicating strong demand [2]. - The company is maintaining excellent service levels, and the intermodal pricing outlook is improving as truckload capacity exits the market [2]. - In the Logistics segment, Hub Group is onboarding significant new business, particularly in Managed Transportation and Final Mile services [2]. - Brokerage volumes have declined as the company focuses on improving profitability and expanding revenue per load [2]. - The company is taking actions to drive growth, improve profitability, and increase operating cash flows, positioning itself well for long-term growth [2]. Group 2: Nasdaq Deficiency Notice - Hub Group received a notice from Nasdaq on March 19, 2026, indicating non-compliance with Listing Rule 5250(c)(1) due to the failure to timely file its 2025 Form 10-K [3][4]. - The company has 60 calendar days from the notice date to submit a plan to regain compliance, with the possibility of an extension up to 180 days [4]. - The notice does not have an immediate effect on the listing or trading of the company's common stock on Nasdaq [4]. Group 3: Financial Reporting and Restatement - Hub Group requires additional time to complete its year-end financial close process due to the restatement of its financial statements for the first three quarters of 2025 [5]. - The company is assessing the potential impact on its consolidated financial statements for the years ended December 31, 2024, and 2023 [5]. - Hub Group expects to file its Form 10-K as soon as practicable and aims to regain compliance with the Listing Rule within the six-month timeframe [5].

Core Viewpoint - Workhorse Group Inc. is set to discuss its fourth quarter and fiscal year 2025 results and business outlook in a conference call scheduled for March 31, 2026, at 4:30 p.m. Eastern time [1]. Group 1: Conference Call Details - The conference call will follow the issuance of Workhorse's fourth quarter and fiscal year 2025 earnings press release, which will be available on the company's website [2]. - Investors can listen to the conference call via telephone by calling (877)-407-0789 for U.S. participants or (201)-689-8562 for international participants [3]. - A telephonic replay of the conference call will be available after 7 p.m. Eastern time on the same day through April 7, 2026, with specific toll-free and international replay numbers provided [3]. Group 2: Company Overview - Workhorse Group Inc. is headquartered in the Detroit area and operates a commercial-scale manufacturing plant in Indiana, focusing on electric trucks, shuttles, and buses [3]. - The company emphasizes its commitment to building software-first electric vehicles that are powerful, cost-efficient, reliable, safe, and comfortable, all while producing zero tailpipe emissions [3]. - Workhorse aims to help customers lower operating costs, improve fleet performance, enhance driver experience, and maximize uptime through electrification, aligning with financial, sustainability, and compliance goals [4].

Core Viewpoint - Phillips Edison & Company, Inc. (PECO) is set to announce its First Quarter 2026 earnings results on April 23, 2026, after market close, with a conference call scheduled for April 24, 2026, at 12:00 p.m. ET [1][2][6] Company Overview - PECO is one of the largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers in the United States, founded in 1991 [4] - As of December 31, 2025, PECO managed 324 shopping centers, including 297 wholly-owned centers totaling 33.5 million square feet across 31 states, and 27 centers owned in three institutional joint ventures [4] - The company focuses on creating omni-channel grocery-anchored shopping experiences and improving communities through its shopping centers [4] Earnings Conference Call Details - The earnings conference call will be hosted by Chairman and CEO Jeff Edison, President Bob Myers, and CFO John Caulfield [1] - A webcast replay will be available approximately one hour after the event [3] - The conference call can be accessed via a toll-free dial-in number (800) 715-9871 and a toll dial-in number (646) 307-1963, with a conference ID of 4551083 [6]

Core Viewpoint - PDS Biotechnology Corporation is set to host a conference call and webcast on March 30, 2026, to report its financial results for the year ended December 31, 2025, and provide updates on clinical programs and corporate developments [1]. Group 1: Conference Call Details - The conference call is scheduled for March 30, 2026, at 8:00 a.m. Eastern Time [2]. - Dial-in numbers include 1-877-704-4453 for domestic calls and 1-201-389-0920 for international calls [2]. - The event will be archived on PDS Biotech's website for six months following the live webcast [2]. Group 2: Company Overview - PDS Biotechnology is a late-stage immunotherapy company focused on enhancing the immune system's ability to target and eliminate cancers [3]. - The company has initiated a pivotal clinical trial for its lead program targeting advanced HPV16-positive head and neck squamous cell cancers [3]. - PDS0101, the lead investigational targeted immunotherapy, is being developed in combination with a standard immune checkpoint inhibitor and in a triple combination with PDS01ADC, an IL-12 fused antibody drug conjugate [3].

Core Insights - Comstock Inc. has transitioned from a junior mining opportunity to a leading metals recovery company, achieving significant milestones in solar recycling and critical metals recovery [2][4] - The company has established two high-growth businesses: a Nevada-based metals recovery operation and an Oklahoma-based renewable fuels company, both with strategic partnerships [2][4] Financial Highlights - Comstock completed an oversubscribed equity financing of $57.5 million, netting $53.0 million after expenses, enhancing its capital base for growth [7] - The company eliminated all debt obligations, resulting in a strong financial position for further growth and monetization of non-core assets [7] - Cash and cash equivalents were reported at $17.0 million as of December 31, 2025, increasing to $56.1 million by March 20, 2026 [7] Operational Achievements - Comstock has received all necessary permits for its first industry-scale facility, with operations expected to commence in the second quarter of 2026 [5][9] - The company is the only certified R2v3/RIOS Responsible Recycling Standard by SERI for solar panel recycling, ensuring a zero-landfill process [8][9] - The first facility is designed to recycle up to 3.3 million panels annually, with commissioning activities underway [19] Strategic Developments - The company has expanded its board with three experienced independent directors, reflecting strong support from major shareholders [7][4] - Comstock is actively pursuing additional site selections for future industry-scale facilities and storage sites [20][26] - Bioleum Corporation, a spin-off focused on renewable fuels, has secured significant investments and is advancing its production capabilities [15][16] Market Outlook - The company aims to set the global standard for solar panel recycling and to commercialize technologies for renewable fuels from waste and energy crops [17][18] - Comstock's mining assets are well-positioned for monetization, with ongoing discussions with sophisticated mining companies [11][23] - The company plans to expand its national footprint in solar panel recycling and enhance its refining capabilities for higher-purity metals [29][20]

Core Insights - BioStem Technologies, Inc. reported a significant decline in revenue for Q4 2025, with net revenue of $10.1 million, a 55% decrease compared to Q4 2024, primarily due to reimbursement uncertainty and competitive pressures [5][6] - The company completed the acquisition of BioTissue Holdings Inc. in January 2026, which is expected to enhance its product portfolio and commercial reach [9][10] - BioStem anticipates first quarter 2026 revenue to be between $5 million and $6 million, with expectations for growth in the hospital business in the second half of the year [12] Recent Financial and Business Highlights - CEO Jason Matuszewski emphasized the company's strengthened position and diversification following the BioTissue acquisition, which expands its market presence [3] - The gross profit margin for Q4 2025 was 97%, up from 84% in Q4 2024, attributed to a shift in product mix [5] - Operating expenses increased to $17.3 million in Q4 2025 from $10.7 million in Q4 2024, largely due to charges for potentially uncollectible accounts receivable [6] Financial Results Overview - For the full year 2025, net revenue was $47.5 million, down from $69.7 million in 2024, driven by lower wound care volume [8] - Gross profit for 2025 was $44.4 million, or 94% of net revenue, compared to $55.9 million or 80% in 2024 [10] - The company reported a GAAP net loss of $6.6 million for 2025, a significant decline from a net income of $31 million in 2024 [11] Cash Position and Future Outlook - As of December 31, 2025, cash equivalents totaled $29.5 million, which decreased to approximately $16 million post-BioTissue acquisition [7] - The company expects to drive sequential and year-over-year growth in the hospital business after integrating the BioTissue assets and expanding its salesforce [12]

Core Insights - Biomea Fusion, Inc. has made significant progress in clinical trials for its lead asset, icovamenib, targeting type 2 diabetes, with promising 52-week clinical data reported [2][5] - The company has initiated two Phase II trials for icovamenib and advanced its next-generation oral GLP-1 receptor agonist, BMF-650, into a Phase I study [2][4] - Financial results for the year ended December 31, 2025, show a net loss of $61.8 million, a reduction from $138.4 million in 2024, indicating improved financial management [7][14] Clinical Development - Icovamenib demonstrated a persistent 1.2% mean reduction in HbA1c in patients with type 2 diabetes, maintained through Week 52 after a 12-week treatment [5] - Two Phase II trials, COVALENT-211 and COVALENT-212, have been initiated, with primary endpoint data expected in the fourth quarter of 2026 [4][11] - BMF-650 is undergoing a Phase I trial, with initial 28-day weight reduction data anticipated in the second quarter of 2026 [4][11] Financial Performance - As of December 31, 2025, the company reported cash, cash equivalents, and restricted cash of $56.2 million, a slight decrease from $58.6 million in 2024 [11][17] - Research and Development (R&D) expenses decreased to $62.0 million in 2025 from $118.1 million in 2024, primarily due to a strategic realignment [11][14] - General and Administrative (G&A) expenses also decreased to $19.3 million in 2025 from $26.0 million in 2024, reflecting cost-saving measures [11][14] Company Overview - Biomea Fusion is focused on developing oral small molecule therapies for diabetes and obesity, addressing a significant global health challenge [8] - The company's mission is to deliver transformative treatments for patients with diabetes, obesity, and related conditions [8]